The pCR rate in the I-SPY2 trial with pembrolizumab and SOC chemotherapy was 60% in TNBC and 30% in HR+/HER2- cancers (Nanda et al., 2020), while the GIADA trial demonstrated a pCR rate of 16.3% in IO-treated HR+/HER2- patients (Franzoi et al., 2021; Dieci et al., 2022). The gene discussed is ERBB2; the disease is cancer.